Applying the 2024 European Society of Cardiology Guidelines for the management of elevated blood pressure and hypertension to a Norwegian general population cohort from age 40: data from the Akershus Cardiac Examination 1950 study
Authors' conclusion
A single BP measurement at age 40 identified eBP (130-139/80-89 mm Hg) among one-third of the individuals, yet MACE cases within the eBP category occurred primarily in individuals who were not eligible for medical treatment.
Study context
- Population
- Norwegian general population born in 1950 (Age 40 Programme and ACE 1950 Study), BP at age 40 and 62–65, linked to national health registries
- Participants
- 2,688 participants
- Outcome
- Treatment eligibility under the 2024 European Society of Cardiology (ESC) hypertension guidelines and MACE rates in those with eBP (130-139/80-89 mm Hg)
- Follow-up
- 30 years
Methodological detailsregistry-linked, general population cohort
- Registry-linked
- General population cohort
Main finding
As reported in the abstract
- Elevated BP (eBP) (130-139/80-89 mm Hg) at age 40
- 854 (32%) of 2688
- eBP at age 40 with elevated cardiovascular (CV) risk warranting pharmacological treatment
- 4
- On BP-lowering medication or BP ≥140/90 at age 62-65
- 1657 (61%)
- eBP at age 62-65 eligible for drug treatment
- 64 (8%) out of 851
- Major adverse cardiovascular events (MACEs) in eBP category (BP at age 40) among those eligible for pharmacological treatment
- 2 of the 93
Observational data: associations, not effects.
Original publication
Applying the 2024 European Society of Cardiology Guidelines for the management of elevated blood pressure and hypertension to a Norwegian general population cohort from age 40: data from the Akershus Cardiac Examination 1950 study. Heart. Published 22 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →